Abstract:Abstract Introduction A hypermetabolic state develops after severe burn injury altering volume distribution, creatinine clearance (CrCl), and hepatic metabolism. This ultimately impacts pharmacokinetics of drugs, including enoxaparin, the standard prophylactic venous thromboembolism (VTE) anticoagulant. Understanding specific factors in burn patients that impact the pharmacokinetics of enoxaparin is necessary to reduce rates of VTE. This study aims to identify risk factors associated with subtherapeutic levels of enoxaparin, measured by peak anti-Xa levels, in burn patients. Methods Patients admitted to a regional burn center over a six-month period were included in this retrospective review. Patients on enoxaparin 40mg twice a day (BID) for VTE prophylaxis and had a peak anti-Xa level were included. Exclusion criteria included polytrauma, therapeutic anticoagulation or anti-platelet therapy, a history of chronic kidney disease, cirrhosis, coagulation disorder, heparin induced thrombocytopenia (HIT), or thrombocytopenia at admission. Patient demographics, burn injury characteristics, and lab values for peak anti-Xa levels and admission CrCl were obtained. For prophylactic enoxaparin, a therapeutic level is 0.2-0.4U/mL and a subtherapeutic level is < 0.2U/mL. Patients were separated into groups based on therapeutic or subtherapeutic levels. Differences between groups were evaluated using two-sample t-test or Wilcoxon rank-sum test. Results Both the subtherapeutic and therapeutic groups had 13 patients. No patient developed a symptomatic VTE within 31 days of discharge. There were no significant differences in gender, BMI (30.4 vs 31.6 kg/m2), presence of inhalation injury, or ICU length of stay (5 vs 3 days) between groups. Patients in the subtherapeutic group were significantly younger (38 vs 48 years), with a higher TBSA (22.6% vs 6%), and a higher CrCl at admission (134.2 vs 104.8 mg/dL). In the subtherapeutic group, the highest dose needed to reach a therapeutic level of enoxaparin was 60mg BID and the median final dose was 50mg BID. Conclusions A delay in initiation of VTE prophylaxis is associated with increased rates of VTE in burn patients, and a delay to therapeutic levels of VTE prophylaxis will likely lead to increased rates of VTE as well. Factors associated with a delay to therapeutic enoxaparin levels were age, %TBSA, and CrCl. A uniform standard dose of enoxaparin may not be effective for all burn patients. Applicability of Research to Practice Burn patients are a unique subgroup that require special consideration in every aspect of care, including VTE prophylaxis. Risk factors associated with subtherapeutic enoxaparin levels after burn injury need to be identified to guide the development of effective VTE prophylaxis guidelines.

Enoxaparin induced reactive thrombocytosis: a rare adverse drug reaction

Drug-induced thromboembolism

A rare case of eptifibatide-induced thrombocytopenia

Eptifibatide-induced acute profound thrombocytopenia: A case report

Rare Heparin Induced Thrombocytopenia Type I Reaction in a Hemodialysis Patient: Case Report.

A woman with eptifibatide (integrilin)-induced thrombocytopenia following treatment of a clot in her coronary artery: A case report and literature review

Thrombolytic Efficacy Of Enoxaparin Compared With Unfractionated Heparins In Cardiac Emergency

P8: CHEMOTHERAPY INDUCED IMMUNE THROMBOCYTOPENIA-AN ENTITY TO KEEP IN MIND!

Left main stent thrombosis complicated by eptifibatide-induced acute thrombocytopenia

Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review

Shake it off: A curious case of rigors

Delayed-onset eptifibatide-induced thrombocytopenia

Protamine-induced immune thrombocytopenia

583 Risk Factors Associated with Subtherapeutic Enoxaparin Levels in Burn Patients

Heparin-induced Thrombocytopenia with Anaphylactoid Reaction during Hemodialysis

Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism

Examining an Interaction Between Plasma Exchange and Apixaban Resulting in an Acute Ischemic Stroke

Eptifibatide-Induced Profound Thrombocytopenia After Percutaneous Intervention for Acute Coronary Syndrome: A Challenging Clinical Scenario

Heparin-Induced Hemorrhagic Bullous Dermatosis: A Rare Complication of Unfractionated Heparin

Extreme Reactive Thrombocytosis Caused by Obstructive Nephrolithiasis and Pyelonephritis

Management of heparin-induced thrombocytopenia during extracorporeal membrane oxygenation support: a case of neutropenia caused by argatroban anticoagulation